An AIDS vaccine tested in people, but found to be ineffective, influenced the genetic makeup of the virus that slipped past. The findings suggest new ideas for developing HIV vaccines.
The results were published Feb. 27 in Nature Medicine.
This is the first evidence that vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus. "Selective pressure" refers to environmental demands that favor certain genetic traits over others.
The senior author of the multi-institutional study is Dr. James I. Mullins, University of Washington (UW) professor of microbiology. The research team analyzed the genome sequences in HIV-1 isolated from 68 newly infected volunteers in the STEP HIV-1 vaccine trial. Mullins and the other principal researchers who carried out this study were not involved in the STEP trial.
The STEP trial was a double-blind, Phase 2B test-of-concept of a Merck HIV-1 subtype B vaccine. The vaccine, MRKAd5, was designed to make the body produce infection-fighting white blood cells, commonly called killer T-cells, that could recognize and target specific parts of HIV-1 known as Gag, Pol and Nef.
The STEP trial was conducted at 34 North American, Caribbean, South American and Australian locations where the HIV-1 subtype B was the predominant virus in the local HIV-infected populations. The trial enrolled 3,000 participants.
Preliminary tests indicated the vaccine was encouraging the appearance of the desired virus-attacking cells. More than 75 percent of vaccinated participants produced HIV-1 specific T cells.
Nevertheless, this response to the vaccine did not predict protection. The trial failed. Immunizations were halted, Mullins recalled, after the first interim analysis indicated that the vaccine neither prevented HIV-1 infection nor reduced the load of virus in the body.
"Even though the T-cell responses were not sufficient to prevent infection," Mullins said, "we were interested in whether the vaccine-elicited T-cells had any impact on those strains of HIV-1 that established infections in the study subjects."
The research team tested for a "sieve effect," which, Mullins explained, occurs when a vaccine successfully blocks some strains of virus and not others. The researchers wanted to know, What are the genetic characteristics of those breakthrough viruses that slipped past the immunization barrier erected by the MRKAd5 vaccine?
The research team isolated strains of HIV-1 from both vaccine and placebo recipients in the study, and compared the genetic sequences of the strains. This would help researchers to determine if any changes in the "founder virus" – the virus first detected in the infection – might have helped it evade the vaccine-induced immune response and take hold in the vaccinated individuals.
The researchers identified potential T-cell targets in the protein-producing regions of the founder virus genetic sequences and compared these to the virus protein-targets of the vaccine – Gag, Pol and Nef. The researchers found that the distances for these viral genetic sequences were greater for the viruses taken from the vaccinated individuals, compared to those from the placebo recipients.
The most significant virus genetic site distinguishing vaccine from placebo recipients was in the region known as Gag-84, which was encompassed by several of the viral segments targeted by the vaccine.
Moreover, the researchers said that the extended divergence between the viruses from the vaccinated and the placebo groups was confined only to the sequences for the proteins targeted by the vaccine components (Gag, Pol and Nef) and was not found in other HIV-1 protein sequences. The influence of the vaccine on the virus genotype, Mullins said, was subtle.
Mullins and his team, as well as their collaborators from the STEP trials studies, are doing similar studies of the genetic impact of the Thailand vaccine RV144 on the AIDS virus. The RV144 vaccine was the first to show some probable effectiveness, but its efficacy was not great enough to put it to more general use.
The researchers added that their findings on breakthrough viruses suggest that new vaccines should be designed to put selective pressure on the virus in a controlled manner.
Such a vaccine, Mullins said, should select for genetic mutations in regions of the virus known to be associated with viral control and should avoid selecting for strains that can either escape the immune defense or act as decoys to fool the immune system.
The researchers propose a goal for new designs of vaccines aimed at inducing killer T-cell responses: corner the virus into assuming forms that debilitate it. This would make the infecting virus fitness-impaired – unable to adapt, reproduce in great numbers and cause disease progression.
"Despite the sad results of the STEP trial," Mullins said, "it has provided clues to ways for science to go forward in the search for an HIV vaccine.
The research was supported by a grant from the U.S. Public Health Service.
In addition to Mullins, others on the research team were: Morgane Rolland, Sodsai Tovanabutra, Allan C. decamp, Nicole Frahm, Peter B. Gilbert, Eric Sanders-Buell, Laura Heath, Craig A. Margaret, Meera Bose, Andrea Bradfield, Annemarie O'Sullivan, Jacqueline Crossler, Teresa Jones, Marty Nau, Kim Wong, Hong Zhoa, Dana N. Raugi, Stephanie Sorensen, Julia Stoddard, Brandon S. Maust, Wenjie Deng, John Hural, Sheri Dubey, Nelson L. Michael, John Shiver, Lawrence Corey, Fusheng Li, Stephen G. Self., Jerome Kim, Susan Buchbinder, Danilo R. Casimiro, Michael N. Robertson, Ann Duerr, M. Juliana McElrath, and Francine E. McCutchan.
The researchers are from these institutions: Department of Microbiology, University of Washington; U.S. Military Research Program, Rockville, Md.; Vaccine and Infectious Disease Institute, Fred Hutchison Cancer Research Center; Merck Research Laboratories, West Point, Pa.; San Francisco Department of Health, and the Bill & Melinda Gates Foundation.
Leila Gray | EurekAlert!
Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz
Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
29.05.2017 | Physics and Astronomy
29.05.2017 | Physics and Astronomy
29.05.2017 | Earth Sciences